Tasma Harindhanavudhi, MD, MS: No financial relationships to disclose
Presentation Description / Summary: This presentation will be discussed the sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors), anti-diabetic drug that have emerged as a significant therapeutic option in the management of type 2 diabetes (T2DM) over the past decade. This session will summarize the mechanism and clinical implications of SGLT2 inhibitors in patients wtih T2DM. Moreover, this session will discuss cardiovascular and renal benefits that positioned SGLT2 inhibitors as a cornerstone in the management of patients with T2DM with chronic kidney disease as well patients wtih established CVD and heart failure.
Learning Objectives:
Upon completion, participant will be able to understand the physiology of renal handling of glucose
Upon completion, participant will be able to describe the mechanism of action of sodium-glucose co-transporter 2 (SGLT2) inhibitor
Upon completion, participant will be able to understand the cardio-renal protective effect of SGLT2 inhibitor
.png)
